Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
As of close of business last night, Ideaya Biosciences Inc’s stock clocked out at $18.08, up 1.46% from its previous closing price of $17.82. In other words, the price has increased by $1.46 from its previous closing price. On the day, 0.84 million shares were traded.
Ratios:
To gain a deeper understanding of IDYA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 13.92 and its Current Ratio is at 13.92. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Stephens on November 18, 2024, initiated with a Overweight rating and assigned the stock a target price of $51.
On November 05, 2024, Leerink Partners Downgraded its rating to Market Perform which previously was Outperform but kept the price unchanged to $27.
On October 24, 2024, UBS started tracking the stock assigning a Buy rating and target price of $50.UBS initiated its Buy rating on October 24, 2024, with a $50 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 26 ’24 when Jason Throne bought 75,000 shares for $40.22 per share.
WHITE MICHAEL ANTHONY sold 28,500 shares of IDYA for $1,032,884 on May 29 ’24. The Chief Scientific Officer now owns 0 shares after completing the transaction at $36.24 per share.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 226.21 while its Price-to-Book (P/B) ratio in mrq is 1.55.
Stock Price History:
Over the past 52 weeks, IDYA has reached a high of $44.42, while it has fallen to a 52-week low of $13.45. The 50-Day Moving Average of the stock is 1.70%, while the 200-Day Moving Average is calculated to be -30.96%.
Shares Statistics:
A total of 87.57M shares are outstanding, with a floating share count of 78.78M. Insiders hold about 7.65% of the company’s shares, while institutions hold 100.99% stake in the company.
Earnings Estimates
The market rating for Ideaya Biosciences Inc (IDYA) is a result of the insights provided by 8.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$0.78, with high estimates of -$0.58 and low estimates of -$0.86.
Analysts are recommending an EPS of between -$2.62 and -$3.48 for the fiscal current year, implying an average EPS of -$3.11. EPS for the following year is -$2.82, with 8.0 analysts recommending between -$2.12 and -$3.83.
Revenue Estimates
Based on 11 analysts’ estimates, the company’s revenue will be $61.68M in the next fiscal year. The high estimate is $174.47M and the low estimate is $10M.
